Literature DB >> 26301691

Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection.

Hadi M Yassine1, Jeffrey C Boyington1, Patrick M McTamney1, Chih-Jen Wei1, Masaru Kanekiyo1, Wing-Pui Kong1, John R Gallagher2, Lingshu Wang1, Yi Zhang1, M Gordon Joyce1, Daniel Lingwood1, Syed M Moin1, Hanne Andersen3, Yoshinobu Okuno4, Srinivas S Rao1, Audray K Harris2, Peter D Kwong1, John R Mascola1, Gary J Nabel1, Barney S Graham1.   

Abstract

The antibody response to influenza is primarily focused on the head region of the hemagglutinin (HA) glycoprotein, which in turn undergoes antigenic drift, thus necessitating annual updates of influenza vaccines. In contrast, the immunogenically subdominant stem region of HA is highly conserved and recognized by antibodies capable of binding multiple HA subtypes. Here we report the structure-based development of an H1 HA stem-only immunogen that confers heterosubtypic protection in mice and ferrets. Six iterative cycles of structure-based design (Gen1-Gen6) yielded successive H1 HA stabilized-stem (HA-SS) immunogens that lack the immunodominant head domain. Antigenic characterization, determination of two HA-SS crystal structures in complex with stem-specific monoclonal antibodies and cryo-electron microscopy analysis of HA-SS on ferritin nanoparticles (H1-SS-np) confirmed the preservation of key structural elements. Vaccination of mice and ferrets with H1-SS-np elicited broadly cross-reactive antibodies that completely protected mice and partially protected ferrets against lethal heterosubtypic H5N1 influenza virus challenge despite the absence of detectable H5N1 neutralizing activity in vitro. Passive transfer of immunoglobulin from H1-SS-np-immunized mice to naive mice conferred protection against H5N1 challenge, indicating that vaccine-elicited HA stem-specific antibodies can protect against diverse group 1 influenza strains.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26301691     DOI: 10.1038/nm.3927

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  45 in total

1.  Accurate determination of local defocus and specimen tilt in electron microscopy.

Authors:  Joseph A Mindell; Nikolaus Grigorieff
Journal:  J Struct Biol       Date:  2003-06       Impact factor: 2.867

2.  Atomic structure of a thermostable subdomain of HIV-1 gp41.

Authors:  K Tan; J Liu; J Wang; S Shen; M Lu
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

3.  Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.

Authors:  David J DiLillo; Gene S Tan; Peter Palese; Jeffrey V Ravetch
Journal:  Nat Med       Date:  2014-01-12       Impact factor: 53.440

4.  Improved sensitivity in flow cytometric intracellular ionized calcium measurement using fluo-3/Fura Red fluorescence ratios.

Authors:  E J Novak; P S Rabinovitch
Journal:  Cytometry       Date:  1994-10-01

5.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

6.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

7.  Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies.

Authors:  Sinthujan Jegaskanda; Emma R Job; Marit Kramski; Karen Laurie; Gamze Isitman; Robert de Rose; Wendy R Winnall; Ivan Stratov; Andrew G Brooks; Patrick C Reading; Stephen J Kent
Journal:  J Immunol       Date:  2013-01-14       Impact factor: 5.422

8.  Role of conformational sampling in computing mutation-induced changes in protein structure and stability.

Authors:  Elizabeth H Kellogg; Andrew Leaver-Fay; David Baker
Journal:  Proteins       Date:  2010-12-03

9.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Authors:  Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  275 in total

1.  Viral infection: Stemming influenza viruses.

Authors:  Cláudio Nunes-Alves
Journal:  Nat Rev Microbiol       Date:  2015-09-07       Impact factor: 60.633

2.  Stabilizing prospects for a universal flu vaccine.

Authors: 
Journal:  Nat Biotechnol       Date:  2015-10       Impact factor: 54.908

3.  Host immunity and pathogen diversity: A computational study.

Authors:  Tomás Aquino; Ana Nunes
Journal:  Virulence       Date:  2016       Impact factor: 5.882

4.  Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses.

Authors:  Nicholas C Wu; Andrew J Thompson; Juhye M Lee; Wen Su; Britni M Arlian; Jia Xie; Richard A Lerner; Hui-Ling Yen; Jesse D Bloom; Ian A Wilson
Journal:  Science       Date:  2020-06-19       Impact factor: 47.728

5.  A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice.

Authors:  Alec W Freyn; Jamile Ramos da Silva; Victoria C Rosado; Carly M Bliss; Matthew Pine; Barbara L Mui; Ying K Tam; Thomas D Madden; Luís Carlos de Souza Ferreira; Drew Weissman; Florian Krammer; Lynda Coughlan; Peter Palese; Norbert Pardi; Raffael Nachbagauer
Journal:  Mol Ther       Date:  2020-04-19       Impact factor: 11.454

6.  Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.

Authors:  Donald M Carter; Christopher A Darby; Bradford C Lefoley; Corey J Crevar; Timothy Alefantis; Raymond Oomen; Stephen F Anderson; Tod Strugnell; Guadalupe Cortés-Garcia; Thorsten U Vogel; Mark Parrington; Harold Kleanthous; Ted M Ross
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

Review 7.  What Are the Most Powerful Immunogen Design Vaccine Strategies? A Structural Biologist's Perspective.

Authors:  Peter D Kwong
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-11-01       Impact factor: 10.005

Review 8.  From Original Antigenic Sin to the Universal Influenza Virus Vaccine.

Authors:  Carole Henry; Anna-Karin E Palm; Florian Krammer; Patrick C Wilson
Journal:  Trends Immunol       Date:  2017-08-31       Impact factor: 16.687

Review 9.  Structural insights into the design of novel anti-influenza therapies.

Authors:  Nicholas C Wu; Ian A Wilson
Journal:  Nat Struct Mol Biol       Date:  2018-02-02       Impact factor: 15.369

Review 10.  A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.

Authors:  Boopathy Ramakrishnan; Karthik Viswanathan; Kannan Tharakaraman; Vlado Dančík; Rahul Raman; Gregory J Babcock; Zachary Shriver; Ram Sasisekharan
Journal:  Trends Microbiol       Date:  2016-10-14       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.